{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:08:39Z","timestamp":1790366919065,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2018.00312","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T04:18:55Z","timestamp":1528258735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves\u2019 Disease\u2014Report of a Challenging Case and Literature Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Rita","family":"Bettencourt-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu\u00e9","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Belo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Queir\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1210\/jc.2004-2231","article-title":"Clinical review: diagnosis and management of pituitary carcinomas","volume":"90","author":"Kaltsas","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","volume-title":"Williams Textbook of Endocrinology","author":"Melmed","year":"2016"},{"key":"B5","volume-title":"Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis","year":"2004"},{"key":"B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-015-0229-8","article-title":"Histological criteria for atypical pituitary adenomas \u2013 data from the German pituitary adenoma registry suggests modifications","volume":"3","author":"Miermeister","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e5268","DOI":"10.1097\/MD.0000000000005268","article-title":"Genetic aspects of pituitary carcinoma: a systematic review","volume":"95","author":"Yang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas \u2013 diagnosis and emerging treatments","volume":"10","author":"Di Ieva","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10143-014-0525-y","article-title":"Invasive adenoma and pituitary carcinoma: a SEER database analysis","volume":"37","author":"Hansen","year":"2014","journal-title":"Neurosurg Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00066-007-1706-1","article-title":"Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome","volume":"183","author":"Langsenlehner","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"B12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1210\/jc.2013-2409","article-title":"The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis","volume":"99","author":"Garmendia Madariaga","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jocn.2015.06.001","article-title":"Current indications for the surgical treatment of prolactinomas","volume":"22","author":"Smith","year":"2015","journal-title":"J Clin Neurosci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.wneu.2017.01.110","article-title":"Endoscopic endonasal versus microscopic transsphenoidal surgery for recurrent and\/or residual pituitary adenomas","volume":"101","author":"Esquenazi","year":"2017","journal-title":"World Neurosurg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ando.2007.03.008","article-title":"Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy","volume":"68","author":"Christin-Maitre","year":"2007","journal-title":"Ann Endocrinol (Paris)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"key":"B20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/eje.1.02268","article-title":"Malignant prolactinoma: case report and review of the literature","volume":"155","author":"Kars","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B21","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2017"},{"key":"B22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00006123-199601000-00024","article-title":"Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody","volume":"38","author":"Thapar","year":"1996","journal-title":"Neurosurgery"},{"key":"B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ecl.2007.10.005","article-title":"Radiotherapy for pituitary adenomas","volume":"37","author":"Brada","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/nop\/npv059","article-title":"Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports","volume":"3","author":"Ji","year":"2016","journal-title":"Neurooncol Pract"},{"key":"B27","doi-asserted-by":"publisher","first-page":"A465","DOI":"10.1016\/j.autrev.2011.11.009","article-title":"Prolactin and autoimmunity","volume":"11","author":"Shelly","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11102-015-0699-5","article-title":"Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas","volume":"19","author":"Larouche","year":"2016","journal-title":"Pituitary"},{"key":"B29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ctrv.2003.12.003","article-title":"Radiotherapy-induced thyroid disorders","volume":"30","author":"Jereczek-Fossa","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1210\/jcem-24-9-934","article-title":"Hyperthyroidism following secondary hypothyroidism","volume":"24","author":"Taunton","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1756-6614-1-7","article-title":"New onset Graves\u2019 disease as a cause of an adrenal crisis in an individual with panhypopituitarism: brief report","volume":"1","author":"Lewandowski","year":"2008","journal-title":"Thyroid Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"662","DOI":"10.4103\/1119-3077.141447","article-title":"Sheehan\u2019s syndrome co-existing with Graves\u2019 disease","volume":"17","author":"Arpaci","year":"2014","journal-title":"Niger J Clin Pract"},{"key":"B33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4158\/EP10069.CR","article-title":"Autoimmune hyperthyroidism due to secondary adrenal insufficiency: resolution with glucocorticoids","volume":"17","author":"Skamagas","year":"2011","journal-title":"Endocr Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2169\/internalmedicine.38.486","article-title":"Hypercalcemia accompanied by hypothalamic hypopituitarism, central diabetes inspidus and hyperthyroidism","volume":"38","author":"Wada","year":"1999","journal-title":"Intern Med"},{"key":"B35","first-page":"232","article-title":"A combined case of macroprolactinoma, growth hormone excess and Graves\u2019 disease","volume":"60","author":"Hussein","year":"2005","journal-title":"Med J Malaysia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1507\/endocrj.44.887","article-title":"Manifestation of primary hyperthyroidism after pituitary adenomectomy: a case report","volume":"44","author":"Otsuka","year":"1997","journal-title":"Endocr J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3892\/ol.2013.1332","article-title":"Grave\u2019s disease induced by radiotherapy for nasopharyngeal carcinoma: a case report and review of the literature","volume":"6","author":"Ma","year":"2013","journal-title":"Oncol Lett"},{"key":"B38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2265.2005.02412.x","article-title":"Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients","volume":"64","author":"Hoshiro","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1056\/NEJMra0804635","article-title":"Predisposing factors for adrenal insufficiency","volume":"360","author":"Bornstein","year":"2009","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12020-013-9933-y","article-title":"Adrenocortical reserves in hyperthyroidism","volume":"45","author":"Agbaht","year":"2014","journal-title":"Endocrine"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T04:18:58Z","timestamp":1528258738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":41,"alternative-id":["10.3389\/fendo.2018.00312"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2018.00312","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"article-number":"312"}}